Back to results
US 11,999,971 B2Granted
Stem cell derived islet differentiation
AssigneeVertex Pharmaceuticals Incorporated
InventorsFelicia J. Pagliuca, George Harb, Lillian Ye
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
Claims20
An in vitro composition comprising a population of cells derived from stem cells in vitro, wherein:
- a) at least 30% of the cells in the population express NKX6.1 and ISL1;
- b) at least 30% of the cells in the population express ISL1 but do not express NKX6.1;
- c) the population comprises cells that express NKX6.1 but do not express ISL1, and less than 25% of the cells in the population express NKX6.1 but do not express ISL1;
- d) less than 25% of the cells in the population express VMAT1;
- and
- e) the population comprises at least one cell that is genetically modified.
3 more elements
Dependencies are inferred from the claim text.